SCLP - SCANCELL HOLDINGS - Share Chat

Scancell Holdings plc is a UK-based, clinical-stage biotechnology company listed on AIM, focused on developing novel immunotherapies for cancer. The company leverages two proprietary technology platforms: ImmunoBody® and Moditope®, designed to generate robust and targeted T-cell immune responses against a broad spectrum of tumour types.

Key pipeline candidates include Modi-1, a Moditope® vaccine targeting modified citrullinated proteins, currently in Phase 1/2 clinical trials for solid tumours, and SCIB1, an ImmunoBody® vaccine which has shown promising results in melanoma trials. As a research-intensive firm, Scancell’s valuation is inherently tied to clinical trial progress, regulatory approvals, and the potential commercialisation of its innovative oncology treatments. It represents a high-growth, high-risk opportunity within the rapidly evolving cancer immunotherapy landscape.